Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: A monkey PET study with [11C](+)3-MPB

NeuroImage

Volumn 58, Issue 1, 2011, Pages 1-9

  Yamamoto, Shigeyuki ^a,c   Maruyama, Shuji ^b   Ito, Yoshihiko ^b   Kawamata, Masahiro ^c   Nishiyama, Shingo ^c   Ohba, Hiroyuki ^c   Yamada, Shizuo ^b   Tsukada, Hideo ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Cognition; Imidafenacin; Monkey; Muscarinic receptor; Oxybutynin; PET

Indexed keywords

IMIDAFENACIN; MUSCARINIC RECEPTOR; N METHYL 3 PIPERIDYL BENZILATE C11; OXYBUTYNIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; BRAIN FUNCTION; BRAIN STEM; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REACTION TIME; THALAMUS;

ALGORITHMS; ANIMALS; BRAIN; BRAIN CHEMISTRY; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; FORM PERCEPTION; IMIDAZOLES; LYSINE; MACACA MULATTA; MALE; MALEIMIDES; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; PHOTIC STIMULATION; POSITRON-EMISSION TOMOGRAPHY; PSYCHOMOTOR PERFORMANCE; RADIOPHARMACEUTICALS; RECEPTORS, MUSCARINIC;

EID: 79960633549     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.06.031     Document Type: Article

References (72)

1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., Van Kerrebroeck P., Victor A., Wein A. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003, 61:37-49. Standardisation Sub-Committee of the International Continence Society.
2. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990, 13:266-271.
3. Ancelin M.L., Artero S., Portet F., Dupuy A.M., Touchon J., Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006, 332:455-459.
4. Andersson K.E. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997, 50:74-84.
5. Bartus R.T., Johnson H.R. Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol. Biochem. Behav. 1976, 5:39-46.
6. Broersen L.M., Heinsbroek R.P., de Bruin J.P., Joosten R.N., van Hest A., Olivier B. Effects of local application of dopaminergic drugs into the dorsal part of the medial prefrontal cortex of rats in a delayed matching to position task: comparison with local cholinergic blockade. Brain Res. 1994, 645:113-122.
7. Broks P., Preston G.C., Traub M., Poppleton P., Ward C., Stahl S.M. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 1988, 26:685-700.
8. Bymaster F.P., Felder C., Ahmed S., McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2002, 1:163-181.
9. Chafee M.V., Goldman-Rakic P.S. Matching patterns of activity in primate prefrontal area 8a and parietal area 7ip neurons during a spatial working memory task. J. Neurophysiol. 1998, 79:2919-2940.
10. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 1986, 19:1-28.
11. Donnellan C.A., Fook L., McDonald P., Playfer J.R. Oxybutynin and cognitive dysfunction. BMJ 1997, 315:1363-1364.
12. de Groat W.C., Nadelhaft I., Milne R.J., Booth A.M., Morgan C., Thor K. Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine. J. Auton. Nerv. Syst. 1981, 3:135-160.
13. Drachman D.A. Memory and cognitive function in man: does the cholinergic system have a specific role?. Neurology 1977, 27:783-790.
14. Edginton T., Rusted J.M. Separate and combined effects of scopolamine and nicotine on retrieval-induced forgetting. Psychopharmacology 2003, 170:351-357.
15. Flynn D.D., Ferrari-DiLeo G., Mash D.C., Levey A.I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. 1995, 64:1888-1891.
16. Funahashi S., Bruce C.J., Goldman-Rakic P.S. Mnemonic coding of visual space in the monkey's dorsolateral prefrontal cortex. J. Neurophysiol. 1989, 61:331-349.
17. Green A., Ellis K.A., Ellis J., Bartholomeusz C.F., Ilic S., Croft R.J., Phan K.L., Nathan P.J. Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol. Biochem. Behav. 2005, 81:575-584.
18. Hampson R.E., España R.A., Rogers G.A., Porrino L.J., Deadwyler S.A. Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717. Psychopharmacology 2009, 202:355-369.
19. Hannula D.E., Tranel D., Cohen N.J. The long and the short of it: relational memory impairments in amnesia, even at short lags. J. Neurosci. 2006, 26:8352-8359.
20. Haraguchi K., Ito K., Kotaki H., Sawada Y., Iga T. Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies. Drug Metab. Dispos. 1997, 25:675-684.
21. Hasselmo M.E., Stern C.E. Mechanisms underlying working memory for novel information. Trends Cogn. Sci. 2006, 10:487-493.
22. Hegde S.S., Eglen R.M. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. 1999, 64:419-428.
23. Herremans A.H., Hijzen T.H., Welborn P.F., Olivier B., Slangen J.L. Effects of infusion of cholinergic drugs into the prefrontal cortex area on delayed matching to position performance in the rat. Brain Res. 1996, 711:102-111.
24. Homma Y., Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int. J. Urol. 2008, 15:986-991.
25. Homma Y., Yamaguchi O. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int. J. Urol. 2009, 16:499-506.
26. Homma Y., Yamaguchi T., Yamaguchi O. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int. J. Urol. 2008, 15:809-815.
27. Inglis W.L., Olmstead M.C., Robbins T.W. Selective deficits in attentional performance on the 5-choice serial reaction time task following pedunculopontine tegmental nucleus lesions. Behav. Brain Res. 2001, 123:117-131.
28. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
29. Jewart R.D., Green J., Lu C.J., Cellar J., Tune L.E. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am. J. Geriatr. Psychiatry 2005, 13:324-328.
30. Katz I.R., Sands L.P., Bilker W., DiFilippo S., Boyce A., D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriatr. Soc. 1998, 46:8-13.
31. Kay G., Crook T., Rekeda L., Lima R., Ebinger U., Arguinzoniz M., Steel M. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur. Urol. 2006, 50:317-326.
32. Kitabatake Y., Hikida T., Watanabe D., Pastan I., Nakanishi S. Impairment of reward-related learning by cholinergic cell ablation in the striatum. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7965-7970.
33. Kobayashi F., Yageta Y., Segawa M., Matsuzawa S. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 2007, 57:92-100.
34. Kobayashi F., Yageta Y., Yamazaki T., Wakabayashi E., Inoue M., Segawa M., Matsuzawa S. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 2007, 57:147-154.
35. Kubo T., Fukuda K., Mikami A., Maeda A., Takahashi H., Mishina M., Haga T., Haga K., Ichiyama A., Kangawa K., Kojima M., Matsuo H., Hirose T., Numa S. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986, 323:411-416.
36. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16:834-840.
37. Maruyama S., Tsukada H., Nishiyama S., Kakiuchi T., Fukumoto D., Oku N., Yamada S. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J. Pharmcol. Exp. Ther. 2008, 325:774-781.
38. Miller R.J., Hiley C.R. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature 1974, 248:596-597.
39. Mitchell A.S., Dalrymple-Alford J.C., Christie M.A. Spatial working memory and the brainstem cholinergic innervation to the anterior thalamus. J. Neurosci. 2002, 22:1922-1928.
40. Nishiyama S., Tsukada H., Sato K., Kakiuchi T., Ohba H., Harada N., Takahashi K. Evaluation of PET ligands (+)N-[(11)C]ethyl-3-piperidyl benzilate and (+)N-[(11)C]propyl-3-piperidyl benzilate for muscarinic cholinergic receptors: a PET study with microdialysis in comparison with (+)N-[(11)C]methyl-3-piperidyl benzilate in the conscious monkey brain. Synapse 2001, 40:159-169.
41. Ohno T., Nakade S., Nakayama K., Kitagawa J., Ueda S., Miyabe H., Masuda Y., Miyata Y. Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br. J. Clin. Pharmacol. 2008, 65:197-202.
42. Ohno M., Yamamoto T., Watanabe S. Effects of intrahippocampal injections of N-methyl-D-aspartate receptor antagonists and scopolamine on working and reference memory assessed in rats by a three-panel runway task. J. Pharmacol. Exp. Ther. 1992, 263:943-950.
43. Ohtake A., Saitoh C., Yuyama H., Ukai M., Okutsu H., Noguchi Y., Hatanaka T., Suzuki M., Sato S., Sasamata M., Miyata K. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol. Pharm. Bull. 2007, 30:54-58.
44. Owen A.M. The role of the lateral frontal cortex in mnemonic processing: the contribution of functional neuroimaging. Exp. Brain Res. 2000, 133:33-43.
45. Oyasu H., Yamamoto T., Sato N., Sawada T., Ozaki R., Mukai T., Ozaki T., Nishii M., Sato H., Fujiwara T., Tozuka Z., Koibuchi Y., Honbo T., Esumi K., Ohtsuka M., Shimomura K. Urinary bladder-selective action of the new antimuscarinic compound vamicamide. Arzneimittelforschung 1994, 44:1242-1249.
46. Penetar D.M., McDonough J.H. Effects of cholinergic drugs on delayed match-to-sample performance of rhesus monkeys. Pharmacol. Biochem. Behav. 1983, 19:963-967.
47. Potter D.D., Pickles C.D., Roberts R.C., Rugg M.D. Scopolamine impairs memory performance and reduces frontal but not parietal visual P3 amplitude. Biol. Psychol. 2000, 52:37-52.
48. Rasmusson D.D., Dudar J.D. Effect of scopolamine on maze learning performance in humans. Experientia 1979, 35:1069-1070.
49. Robbins T.W., Semple J., Kumar R., Truman M.I., Shorter J., Ferraro A., Fox B., McKay G., Matthews K. Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: comparison with diazepam and implications for dementia. Psychopharmacology 1997, 134:95-106.
50. Rusted J.M., Warburton D.M. The effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology 1988, 96:145-152.
51. Sawaguchi T., Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991, 251:947-950.
52. Sellin A.K., Shad M., Tamminga C. Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr. 2008, 13:985-996.
53. Starkman J.S., Dmochowski R.R. Management of overactive bladder with transdermal oxybutynin. Rev. Urol. 2006, 8:93-103.
54. Sugiyama T., Park Y.C., Kurita T. Oxybutynin disrupts learning and memory in the rat passive avoidance response. Urol. Res. 1999, 27:393-395.
55. Supèr H., Spekreijse H., Lamme V.A. A neural correlate of working memory in the monkey primary visual cortex. Science 2001, 293:120-124.
56. Sussman D.O. Overactive bladder: treatment options in primary care medicine. J. Am. Osteopath. Assoc. 2007, 107:379-385.
57. Suzuki M., Noguchi Y., Okutsu H., Ohtake A., Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur. J. Pharmacol. 2007, 557:154-158.
58. Takahashi K., Murakami M., Miura S., Iida H., Kanno I., Uemura K. Synthesis and autoradiographic localization of muscarinic cholinergic antagonist (+)N-[11C]methyl-3-piperidyl benzilate as a potent radioligand for positron emission tomography. Appl. Radiat. Isot. 1999, 50:521-525.
59. Tang Y., Mishkin M., Aigner T.G. Effects of muscarinic blockade in perirhinal cortex during visual recognition. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:12667-12669.
60. Tsukada H., Harada N., Nishiyama S., Ohba H., Kakiuchi T. Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. J. Neurosci. 2000, 20:7067-7073.
61. Tsukada H., Harada N., Ohba H., Nishiyama S., Kakiuchi T. Facilitation of dopaminergic neural transmission does not affect [(11)C]SCH23390 binding to the striatal D(1) dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D(1) receptors: PET studies in the conscious monkey brain. Synapse 2001, 42:258-265.
62. Tsukada H., Kakiuchi T., Nishiyama S., Ohba H., Sato K., Harada N., Takahashi K. Age differences in muscarinic cholinergic receptors assayed with (+)N-[(11)C]methyl-3-piperidyl benzilate in the brains of conscious monkeys. Synapse 2001, 41:248-257.
63. Tsukada H., Takahashi K., Miura S., Nishiyama S., Kakiuchi T., Ohba H., Sato K., Hatazawa J., Okudera T. Evaluation of novel PET ligands (+)N-[11C]methyl-3-piperidyl benzilate ([11C](+)3-MPB) and its stereoisomer [11C](?)3-MPB for muscarinic cholinergic receptors in the conscious monkey brain: a PET study in comparison with [11C]4-MPB. Synapse 2001, 39:182-192.
64. Turchi J., Saunders R.C., Mishkin M. Effects of cholinergic deafferentation of the rhinal cortex on visual recognition memory in monkeys. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2158-2161.
65. t'Veld B.A., Kwee-Zuiderwijk W.J., van Puijenbroek E.P., Stricker B.H. Neuropsychiatric adverse effects attributed to use of oxybutynin. Ned. Tijdschr. Geneeskd. 1998, 142:590-592.
66. Uno T., Kobayashi F., Ogata A., Konomi T. Pharmacological and clinical profile of imidafenacin developed as a new therapeutic agent for overactive bladder. Nippon Yakurigaku Zasshi 2008, 131:379-387.
67. Volpicelli L.A., Levey A.I. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog. Brain Res. 2004, 145:59-66.
68. Watanabe M., Okada H., Shimizu K., Omura T., Yoshikawa E., Kosugi T., Mori S., Yamashita T. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans. Nucl. Sci. 1997, 44:1277-1282.
69. Yamada S., Seki M., Ogoda M., Fukata A., Nakamura M., Ito Y. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder. J. Pharmacol. Exp. Ther. 2011, 336:365-371.
70. Yamamoto S., Nishiyama S., Kawamata M., Ohba H., Wakuda T., Takei N., Tsukada H., Domino E.F. Muscarinic receptor occupancy and cognitive Impairment: A PET Study with [11C](+)3-MPB and scopolamine in conscious monkeys. Neuropsychopharmacology 2011, 36:1455-1465.
71. Yamamoto S., Ohba H., Nishiyama S., Takahashi K., Tsukada H. Validation of reference tissue model of PET ligand [11C](+)3-MPB for the muscarinic cholinergic receptor in the living brain of conscious monkey. Synapse 2010, 65:548-551.
72. Yoshida A., Maruyama S., Fukumoto D., Tsukada H., Ito Y., Yamada S. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. Life Sci. 2010, 87:175-180.